Switch to Dark theme

References

Nayyar P, Kumar P, Nayyar PV, Singh A. Botox: broadening the horizon of dentistry. J Clin Diagn Res. 2014; 8:25-29
Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol. 2005; 53:3-9
Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev. 1981; 33:155-188
Rao LB, Sangur R, Pradeep S. Application of Botulinum toxin Type A: an arsenal in dentistry. Indian J Dent Res. 2011; 22:440-445
Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007; 29:1761-1768
Small R. Botulinum toxin injection for facial wrinkles. AM Fam Physician. 9:168-175
Shilpa PS, Kaul R, Sultana N, Bhat S. Botulinum toxin: the Midas touch. J Nat Sci Biol Med. 2014; 5:8-14
Ham JW. Masseter muscle reduction procedure with radiofrequency coagulation. J Oral Maxillofac Surg. 2009; 67:457-463
Smyth AG. Botulinum toxin treatment of bilateral masseteric hypertrophy. Br J Oral Maxillofac Surg. 1994; 32:29-33
Moore AP, Wood GD. The medical management of masseteric hypertrophy with botulinum toxin type A. Br J Oral Maxillofac Surg. 1994; 32:26-28
Kim HJ, Yum KW, Lee SS, Heo MS, Seo K. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg. 2003; 29:484-489
Al-Ahmad HT, Al-Qudah MA. The treatment of masseter hypertrophy with botulinum toxin type A. Saudi Med J. 2006; 27:397-400
Baş B, Ozan B, Muğlali M, Celebi N. Treatment of masseteric hypertrophy with botulinum toxin: a report of two cases. Med Oral Patol Oral Cir Bucal. 2010; 15:649-652
Rzany B, Ascher B, Fratila A, Monheit GD, Talarico S, Sterry W. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of Botulinum Toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol. 2006; 142:320-326
Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache. 2000; 40:445-450
Behmand RA, Tucker T, Guyuron B. Single-site botulinum toxin type a injection for elimination of migraine trigger points. Headache. 2003; 43:1085-1089
Ashkenazi A. Botulinum toxin type a for chronic migraine. Curr Neurol Neurosci Rep. 2010; 10:140-146
Lynch MA, Brightman VJ, Greenberg MS.Philadelphia: Lippincott; 1994
Freund B, Schwartz M, Symington JM. Botulinum toxin: new treatment for temporomandibular disorders. Br J Oral Maxillofac Surg. 2000; 38:466-471
Van Zandijcke M, Marchau MM. Treatment of bruxism with botulinum toxin injections. J Neurol Neurosurg Psychiatry. 1990; 53
Tan EK, Jankovic JJ. Treating severe bruxism with botulinum toxin. Am Dent Assoc. 2000; 131:211-216
El Maaytah M, Jerjes W, Upile T, Swinson B, Hopper C, Ayliffe P. Bruxism secondary to brain injury treated with botulinum toxin-A: a case report. Head Face Med. 2006; 23
Drobik C, Laskawi R. Frey's syndrome: treatment with botulinum toxin. Acta Otolaryngol. 1995; 115:459-461
Naumann M, Zellner M, Toyka KV, Reiners K. Treatment of gustatory sweating with botulinum toxin. Ann Neurol. 1997; 42:973-975
Laccourreye O, Akl E, Gutierrez-Fonseca R, Garcia D, Brasnu D, Bonan B. Recurrence of gustatory sweating (Frey syndrome) after intracutaneous injection of botulinum toxin type A: incidence, management, and outcome. Arch Otolaryngol Head Neck Surg. 1999; 125:283-286
De Bree R, Duyndam JE, Kuik DJ, Leemans CR. Repeated botulinum toxin type A injections to treat patients with Frey syndrome. Arch Otolaryngol Head Neck Surg. 2009; 135:287-290
Ellies M, Gottstein U, Rohrbach-Volland S, Arglebe C, Laskawi R. Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis. Laryngoscope. 2004; 114:1856-1860
Mancini F, Zangaglia R, Cristina S. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type a in the treatment of drooling in parkinsonism. Mov Disord. 2003; 18:685-688
Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin b for Sialorrhea in Parkinson's disease. Neurology. 2004; 62:37-40
Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type a for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2006; 21:704-707
Capaccio P, Torretta S, Osio M, Minorati D, Ottaviani F, Sambataro G Botulinum toxin therapy: a tempting tool in the management of salivary secretory disorders. Am J Otolaryngol. 2008; 29:333-338
Melling J, Hambleton P, Shone CC. Clostridium botulinum toxins: nature and preparation for clinical use. Eye (Lond). 1988; 2:216-223
Vartainian A, Dayan S. Complications of botulinum toxin A use in facial rejuvenation. Facial Plast Surg Clin N Am. 2005; 13:1-10
Aoki R. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon. 2002; 40:923-928
Kerr G. Safety of Botulinum toxin in cerebral palsy. Toxicon. 2008; 51
Lewis K. Dento-legal aspects of non-surgical facial aesthetic procedures. Fac Dent J. 2014; 5:69-72
General Dental Council. Scope of Practice. 2013. https://www.gdc-uk.org/api/files/Scope%20of%20Practice%20September%202013.pdf (Accessed 15 August 2016)

Botox: It's Not Just About The Wrinkles

From Volume 45, Issue 1, January 2018 | Pages 32-37

Authors

Naomi Prado

BSc(Hons), BDS, MFDS RCPS(Glas)

DCT1 in Oral Surgery, Paediatrics and Orthodontics, University Dental Hospital of Manchester, Higher Cambridge Street, Manchester M15 6FH, UK (n_prado@live.co.uk)

Articles by Naomi Prado

Louisa Rose

BSc(Hons), BDS, MFDS RCPS(Edin)

DCT1 Maxillofacial Surgery, Royal Derby Hospital, Uttoxeter Road, Derby, DE22 3NE, UK

Articles by Louisa Rose

Peter Korczak

MBBS, BDS, FDS RCS, FRCS

Oral and MaxilloFacial Consultant, Royal Derby Hospital, Uttoxeter Road, Derby, DE22 3NE, UK

Articles by Peter Korczak

Abstract

The use of Botulinum toxin (BTX) for cosmetic procedures has been well recognized, however, its popularity and use in treating a variety of conditions within clinical dentistry is continuing to increase. This includes masseteric hypertrophy, neuralgias, temporomandibular joint dysfunction and sialorrhoea, to name just a few.

CPD/Clinical Relevance: To discuss the uses of Botulinum toxin and highlight the importance of ensuring safety and informed consent in regard to BTX use in clinical practice.

Article

The use of Botulinum toxin (BTX) for cosmetic treatments has been well recognized within the literature and commonly reflected in the media. However, the Botulinum toxin is derived from a variety of other therapeutic uses.1 With its increasing popularity in clinical dentistry and further developments in pharmacology, there has been increased understanding of the use of BTX to treat a variety of orofacial conditions. With further MHRA (Medicines and Healthcare products Regulatory Agency) approvals, the use and merit of BTX as a minimally invasive clinical adjunct to existing treatments is continuing to broaden the horizons of clinical dentistry.1

Botulinum toxin is produced from the bacterium Clostridium botulinum and is a neurotoxin of which there are seven subtypes, ranging from A–G.2 The most common forms of this toxin are Types A and B, which have multiple clinical applications.3

Register now to continue reading

Thank you for visiting Dental Update and reading some of our resources. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Up to 2 free articles per month
  • New content available

Already have an account? Sign in here